Some PetMed Express (NASDAQ:PETS) Shareholders Have Copped A Big 57% Share Price Drop

The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of PetMed Express, Inc. (NASDAQ:PETS) have suffered share price declines over the last year. The share price has slid 57% in that time. However, the longer term returns haven't been so bad, with the stock down 21% in the last three years. The falls have accelerated recently, with the share price down 17% in the last three months. We note that the company has reported results fairly recently; and the market is hardly delighted. You can check out the latest numbers in our company report.

See our latest analysis for PetMed Express

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

Unhappily, PetMed Express had to report a 25% decline in EPS over the last year. This reduction in EPS is not as bad as the 57% share price fall. This suggests the EPS fall has made some shareholders are more nervous about the business. The P/E ratio of 10.90 also points to the negative market sentiment.

NasdaqGS:PETS Past and Future Earnings, August 9th 2019
NasdaqGS:PETS Past and Future Earnings, August 9th 2019

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. This free interactive report on PetMed Express's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

Advertisement

What About Dividends?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of PetMed Express, it has a TSR of -55% for the last year. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

A Different Perspective

Investors in PetMed Express had a tough year, with a total loss of 55% (including dividends), against a market gain of about 3.3%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 7.0% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. If you would like to research PetMed Express in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqGS:PETS

PetMed Express

Operates as a pet pharmacy in the United States.

Excellent balance sheet with moderate growth potential.

Advertisement

Weekly Picks

CE
Ceazar
CNXU logo
Ceazar on Conexeu Sciences Ā·

This small biotech is developing technology that could potentially change how tissue is rebuilt

Fair Value:US$25.3451.9% undervalued
50 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
HE
HedgeY
PWR logo
HedgeY on Quanta Services Ā·

The Picks-and-Shovels Leader of the Grid Supercycle

Fair Value:US$7104.2% overvalued
52 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
FU
KRMN logo
FundamentalFlow on Karman Holdings Ā·

KRMN — Karman Space & Defense: Down 58% from Peak, Is the Market Mispricing a Hypergrowth Defense Compounder?

Fair Value:US$105.654.8% undervalued
34 users have followed this narrative
2 users have commented on this narrative
16 users have liked this narrative
DO
Double_Bubbler
IES logo
Double_Bubbler on Invinity Energy Systems Ā·

Invinity Energy Systems: All About That BESS

Fair Value:UKĀ£161.9% undervalued
40 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

JA
Jacobm2488123
NFLX logo
Jacobm2488123 on Netflix Ā·

Netflix's Revenue Surge Will Hit 18% Despite Market Lows

Fair Value:US$115.9137.1% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
LO
Lou_Basenese
VTIX logo
Lou_Basenese on Virtuix Holdings Ā·

From a ā€œShark Tankā€ Snub to an Air Force ā€œYesā€: Why Virtuix at $3.50 May Be the Market’sMost Mispriced AI Story

Fair Value:US$7.551.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
SPCX logo
browser on Space Exploration Technologies Ā·

SpaceX: A Sober Look at Catalysts, Risks, and Long‑Term Value After the IPO

Fair Value:US$0.4633.5k% overvalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings Ā·

Investment Analysis (May 2026)

Fair Value:US$22.7443.8% undervalued
67 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe Ā·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9639.1% undervalued
61 users have followed this narrative
9 users have commented on this narrative
17 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile Ā·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17056.9% undervalued
51 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative